OBJECTIVES

Lung cancer (LC) is one of the leading cancer pathology and cause of death in Russia, which incidence is still growing. In Russia >70% of newly, diagnosed patients have III or IV disease stage. According to North-West regional cancer register the mortality during the first year after diagnosis is 58,6%.

METHODS

The aim of the study was to calculate LC direct medical costs and it’s structure using real-world data. We analyzed medical services received by patients with LC in North-West region of Russia in 2019 from the data of national cancer register, electronic medical records, governmental medical insurance system. Inpatient and outpatient care of patients diagnosed in 2019 we analyzed in details from the date of diagnosis. The information from the different sources (databases) we merged using patient insurance ID in order to build patient's medical care history using the real-world data. Governmental insurance tariffs (cost of medical services) were used for total costs calculation. Patient’s out of pocket expenditures were not included.

RESULTS

In 2019 in North-West region of Russia 8191 patients with LC (5980 newly diagnosed) received healthcare services, which total direct medical costs are 1,1 billion RUR (15,6 million USD), 135293RUR/patient. The share of inpatient care including surgery, radiology and systemic drug therapy is 93%. The share of outpatient care is 7%, the average number of outpatient visits is 7 per patient/year. The average cost of care during the first year after diagnosis is the highest – 433650RUR/patient/year: 34% - surgery, 11% - radiology, 52% - systemic drug therapy, 3% - outpatient care.

CONCLUSIONS

LC real-world costs in Russia are significant and still growing, especially because of the late diagnosis. The average cost of first year after diagnosis is 3,2 times higher comparing to second and further years, mostly due to surgery and systemic drug (chemotherapy, targeted, immunotherapy) costs.